Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.

Cancer Metastasis Rev · 2020 · PMC7497299 · PMID 32367253

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although the studies showed a trend towards longer survival and better response rates in patients with decreasing or undetectable ctDNA levels upon treatment, no statistically significant association between ctDNA level, OS, PFS, or radiological response has been described [ 61 , 63 , 67 , 70 – 72 , 81 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.